VERAXA Biotech Acquired by Voyager Acquisition | Healthcare M&A Deal

Voyager Acquisition acquires VERAXA Biotech, a healthcare services other business in Switzerland, for $1.3 billion. VERAXA Biotech develops novel cancer therapies using its BiTAC technology platform, including functional antibody screening and ADC technology, supporting healthcare M&A interest. Voyager Acquisition acquisitions align with a platform acquisition strategy in healthcare services other, combining drug development pipeline and licensing partnerships to build a public-company pathway. The healthcare M&A is structured as a platform acquisition with private equity acquisition backing, alongside a $27.5 million principal amount senior secured note financing and a $50 million share purchase agreement, with a proposed business combination filing on Form F-4 with the SEC.